Predictors of Interferon-gamma Release Assay Results and Their Association with COVID-19 Infection Outcomes

Overview

Journal IJTLD Open

Date 2024 Oct 14

PMID 39398431

Authors

S J W Kang

G W Eather

F Qureshi

J R Scott

Affiliations

Soon will be listed here.

Abstract

Background: An 'indeterminate' interferon-gamma release assay (IGRA) result used in the diagnosis of latent TB infection (LTBI) is most commonly due to an inadequate control (or 'mitogen') response, which may reflect underlying T-cell dysfunction.

Methods: We performed a single-centre, retrospective study on COVID-19 patients admitted to a tertiary referral hospital who had IGRA testing conducted over a 5-month period. The primary outcomes included predictors of indeterminate IGRA results and associations with COVID-19 outcomes.

Results: A total of 181 patients were included for analysis. Approximately one-third of patients hospitalised with COVID-19 with IGRA testing performed (60/181) had an indeterminate result. The likelihood of an indeterminate IGRA was increased in patients with a history of solid organ transplant and a higher severity of COVID-19 at the time of testing. An indeterminate IGRA was associated with a higher risk of severe COVID-19 and a higher risk of admission to the ICU during admission to the hospital. No difference in mortality between the two subgroups was found.

Conclusion: Our study demonstrated that COVID-19 patients on immunosuppression had a high likelihood of an indeterminate IGRA result, which was associated with markers of disease severity and immunosuppression. In this cohort, an indeterminate result was associated with worse COVID-19 outcomes.

References

Solanich X, Fernandez-Huerta M, Basaez C, Antoli A, Rocamora-Blanch G, Corbella X . Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome. J Clin Med. 2021; 10(5). PMC: 7956705. DOI: 10.3390/jcm10050918. View

Lin L, Lu L, Cao W, Li T . Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020; 9(1):727-732. PMC: 7170333. DOI: 10.1080/22221751.2020.1746199. View

Chatterjee K, Wu C, Bhardwaj A, Siuba M . Steroids in COVID-19: An overview. Cleve Clin J Med. 2020; . DOI: 10.3949/ccjm.87a.ccc059. View

Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H . Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010; 62(10):2876-85. DOI: 10.1002/art.27622. View

Lucas M, Nicol P, McKinnon E, Whidborne R, Lucas A, Thambiran A . A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax. 2010; 65(5):442-8. DOI: 10.1136/thx.2009.127555. View

Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo D, Dilektasli A . Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014; 190(10):1168-76. DOI: 10.1164/rccm.201405-0967OC. View

Sharninghausen J, Shapiro A, Koelle D, Kim H . Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis Infection. Open Forum Infect Dis. 2018; 5(8):ofy184. PMC: 6104778. DOI: 10.1093/ofid/ofy184. View

Soy M, Keser G, Atagunduz P, Tabak F, Atagunduz I, Kayhan S . Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020; 39(7):2085-2094. PMC: 7260446. DOI: 10.1007/s10067-020-05190-5. View

Redelman-Sidi G, Sepkowitz K . IFN-γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2012; 188(4):422-31. DOI: 10.1164/rccm.201209-1621CI. View

10.

Wong S, Gao Q, Tsoi K, Wu W, Tam L, Lee N . Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2015; 71(1):64-72. DOI: 10.1136/thoraxjnl-2015-207811. View

11.

Toor S, Saleh R, Sasidharan Nair V, Taha R, Elkord E . T-cell responses and therapies against SARS-CoV-2 infection. Immunology. 2020; 162(1):30-43. PMC: 7730020. DOI: 10.1111/imm.13262. View

12.

Huang I, Pranata R . Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020; 8:36. PMC: 7245646. DOI: 10.1186/s40560-020-00453-4. View

13.

Ward J, Cornaby C, Schmitz J . Indeterminate QuantiFERON Gold Plus Results Reveal Deficient Interferon Gamma Responses in Severely Ill COVID-19 Patients. J Clin Microbiol. 2021; 59(10):e0081121. PMC: 8451425. DOI: 10.1128/JCM.00811-21. View

14.

Torre A, Aliberti S, Castellotti P, Cirillo D, Grisolia A, Mangioni D . Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy. Respir Med. 2020; 175:106204. PMC: 7645275. DOI: 10.1016/j.rmed.2020.106204. View

15.

Samprathi M, Jayashree M . Biomarkers in COVID-19: An Up-To-Date Review. Front Pediatr. 2021; 8:607647. PMC: 8042162. DOI: 10.3389/fped.2020.607647. View

16.

Brown J, Kumar K, Reading J, Harvey J, Murthy S, Capocci S . Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. Eur Respir J. 2017; 50(4). DOI: 10.1183/13993003.01267-2017. View

17.

Tadolini M, Codecasa L, Garcia-Garcia J, Blanc F, Borisov S, Alffenaar J . Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020; 56(1). PMC: 7251245. DOI: 10.1183/13993003.01398-2020. View

18.

Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S . IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007; 37(10):2695-706. DOI: 10.1002/eji.200737409. View

19.

Gadotti A, Deus M, Telles J, Wind R, Goes M, Garcia Charello Ossoski R . IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020; 289:198171. PMC: 7510544. DOI: 10.1016/j.virusres.2020.198171. View

20.

Bordallo B, Bellas M, Cortez A, Vieira M, Pinheiro M . Severe COVID-19: what have we learned with the immunopathogenesis?. Adv Rheumatol. 2020; 60(1):50. PMC: 7506814. DOI: 10.1186/s42358-020-00151-7. View